CERO Therapeutics Holdings, Inc. announced on June 6, 2025, that it has issued additional shares of its Series D Preferred Stock to institutional investors. This transaction resulted in approximately $750,000 in gross proceeds from this closing, stemming from an option exercise under a securities purchase agreement initially entered into on April 22, 2025.
The original agreement allowed for the issuance of up to $8 million in Series D Preferred Stock, with $5 million previously issued in April 2025. This latest closing means up to $2.25 million of the total $8 million may still be funded at one or more additional closings, at the investors' election.
CEO Chris Ehrlich welcomed this continued support from investors, viewing it as a vote of confidence as the company progresses along its clinical timeline. The net proceeds from this funding are intended to support the two recent FDA IND allowances in liquid and solid tumors and to complete site activation at MD Anderson Cancer Center, as well as bring other sites online quickly.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.